Product Identification

Product Name

Ethyl 2-(4-chlorophenoxy)-2-methylpropionate

Synonyms

2-(P-chlorophenoxy)-2-methylpropionic*acid ethyl
Antilipid
Ateculon
Ethyl 2-(4-chlorophenoxy)-2-methylpropionate
Ethyl clofibrate
Phenoxyisobutyricacidethylester

CAS

637-07-0

Formula

C12H15ClO3

Molecular Weight

242.7

EINECS

211-277-4

RTECS

UE9480000

RTECS Class

Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data

Merck

12,2436

Beilstein/Gmelin

1913459

Beilstein Reference

4-06-00-00851

Physical and Chemical Properties

Appearance

Oil. Faint characteristic odor.

Solubility in water

insoluble

Boiling Point

148

Density

1.138-1.144 g/cm3 (20 C)

Usage

Agent to lower plasma very-low-density-lipoprotein concn, agent to lower concn of plasma triglycerides.

Refractive Index

1.505 (19 C)

First Aid Measures

Ingestion

Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.

Inhalation

If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.

Skin

Remove contaminated clothing. Wash exposed area with soap and water. If symptoms persist, seek medical attention. Launder clothing before reuse.

Eyes

If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Handling and Storage

Storage

Clofibrate liquid-filled capsules should be stored in well-closed, light-resistant containers, at a temperature less than 40C. Preferably at 15-30C; freezing of the liquid-filled capsules should be avoided.

Handling

All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.

Hazards Identification

Skin

Various rashes and alopecia have been reported.

Ingestion

Ausea, vomiting, constipation, dyspepsia, diarrhea, and flatulence occur transiently in approximately 10% of patients. Epigastric pain has been reported as a frequent side effect and cholelithiasis is increased.

Exposure Controls/Personal Protection

Personal Protection

Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.

Respirators

Use NIOSH/MSHA approved respirator appropriate for exposure of concern.

Exposure Effects

with therapeutic use - fatigue, weakness, drowsiness, dizziness, and headache have been reported during clofibrate therapy. Clofibrate and Fenofibrate are classified as FDA Pregnancy Category C.

Fire Fighting Measures

Flash Point

110

Fire Fighting

Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Accidental Release Measures

Small spills/leaks

Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.

Stability and Reactivity

Stability

Sensitive to oxidation and light; easily hydrolyzed.

Incompatibilities

Strong oxidizing agents.